MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318778 | Name: Sulfisoxazole
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulfisoxazole is a sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of Gram-negative and Gram-positive organisms.

Chemical Structure

Sulfisoxazole
Sulfisoxazole
CAS#127-69-5

Theoretical Analysis

MedKoo Cat#: 318778

Name: Sulfisoxazole

CAS#: 127-69-5

Chemical Formula: C11H13N3O3S

Exact Mass: 267.0678

Molecular Weight: 267.30

Elemental Analysis: C, 49.43; H, 4.90; N, 15.72; O, 17.96; S, 11.99

Price and Availability

Size Price Availability Quantity
2g USD 250.00
5g USD 450.00
10g USD 650.00
25g USD 950.00
50g USD 1,450.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NU445; NU-445; NU 445; Sulfisoxazole; Neazolin; Neoxazol
IUPAC/Chemical Name
4-amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide
InChi Key
NHUHCSRWZMLRLA-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
SMILES Code
O=S(NC1=C(C)C(C)=NO1)(C2=CC=C(N)C=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Sulfisoxazole is an endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively.
In vitro activity:
Sulfisoxazole attenuated the elevation of nitric oxide (deduced by measuring nitrite) and the reduction in numbers of GABA-containing neurones caused by LPS. The in vitro studies provided support for the protective effect of sulfisoxazole. Reference: Neurochem Int. 2006 Jun;48(8):708-17. https://pubmed.ncbi.nlm.nih.gov/16464516/
In vivo activity:
Sulfisoxazole, an antibacterial agent, reduces exosomal PD-L1 levels in blood when orally administered to tumor-bearing mice. This reinvigorates exhausted T cells, leading to robust antitumor effects when combined with anti-PD-1 antibody treatment. Sulfisoxazole's ability to inhibit exosomal PD-L1 suggests it could enhance the response rate of anti-PD-1 antibodies. Reference: Adv Sci (Weinh). 2022 Feb;9(5):e2103245. https://pubmed.ncbi.nlm.nih.gov/34927389/

Preparing Stock Solutions

The following data is based on the product molecular weight 267.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Syed H, Safa R, Chidlow G, Osborne NN. Sulfisoxazole, an endothelin receptor antagonist, protects retinal neurones from insults of ischemia/reperfusion or lipopolysaccharide. Neurochem Int. 2006 Jun;48(8):708-17. doi: 10.1016/j.neuint.2005.12.007. Epub 2006 Feb 7. PMID: 16464516. 2. Shin JM, Lee CH, Son S, Kim CH, Lee JA, Ko H, Shin S, Song SH, Park SS, Bae JH, Park JM, Choe EJ, Baek MC, Park JH. Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. Adv Sci (Weinh). 2022 Feb;9(5):e2103245. doi: 10.1002/advs.202103245. Epub 2021 Dec 20. PMID: 34927389; PMCID: PMC8844465. 3. Im EJ, Lee CH, Moon PG, Rangaswamy GG, Lee B, Lee JM, Lee JC, Jee JG, Bae JS, Kwon TK, Kang KW, Jeong MS, Lee JE, Jung HS, Ro HJ, Jun S, Kang W, Seo SY, Cho YE, Song BJ, Baek MC. Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat Commun. 2019 Mar 27;10(1):1387. doi: 10.1038/s41467-019-09387-4. PMID: 30918259; PMCID: PMC6437193.
In vitro protocol:
1. Syed H, Safa R, Chidlow G, Osborne NN. Sulfisoxazole, an endothelin receptor antagonist, protects retinal neurones from insults of ischemia/reperfusion or lipopolysaccharide. Neurochem Int. 2006 Jun;48(8):708-17. doi: 10.1016/j.neuint.2005.12.007. Epub 2006 Feb 7. PMID: 16464516.
In vivo protocol:
1. Shin JM, Lee CH, Son S, Kim CH, Lee JA, Ko H, Shin S, Song SH, Park SS, Bae JH, Park JM, Choe EJ, Baek MC, Park JH. Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. Adv Sci (Weinh). 2022 Feb;9(5):e2103245. doi: 10.1002/advs.202103245. Epub 2021 Dec 20. PMID: 34927389; PMCID: PMC8844465. 2. Im EJ, Lee CH, Moon PG, Rangaswamy GG, Lee B, Lee JM, Lee JC, Jee JG, Bae JS, Kwon TK, Kang KW, Jeong MS, Lee JE, Jung HS, Ro HJ, Jun S, Kang W, Seo SY, Cho YE, Song BJ, Baek MC. Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat Commun. 2019 Mar 27;10(1):1387. doi: 10.1038/s41467-019-09387-4. PMID: 30918259; PMCID: PMC6437193.
1: Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. Drug Chem Toxicol. 2014 Apr;37(2):121-9. doi: 10.3109/01480545.2013.834349. Epub 2013 Oct 7. Review. PubMed PMID: 24099411; PubMed Central PMCID: PMC4105183. 2: Muñoz-Negrete FJ, Pérez-López M, Won Kim HR, Rebolleda G. [New developments in glaucoma medical treatment]. Arch Soc Esp Oftalmol. 2009 Oct;84(10):491-500. Review. Spanish. PubMed PMID: 19902393. 3: McClain RM, Keller D, Casciano D, Fu P, MacDonald J, Popp J, Sagartz J. Neonatal mouse model: review of methods and results. Toxicol Pathol. 2001;29 Suppl:128-37. Review. PubMed PMID: 11695548. 4: Giebink GS. Otitis media prevention: non-vaccine prophylaxis. Vaccine. 2000 Dec 8;19 Suppl 1:S129-33. Review. PubMed PMID: 11163476. 5: Erramouspe J, Heyneman CA. treatment and prevention of otitis media. Ann Pharmacother. 2000 Dec;34(12):1452-68. Review. PubMed PMID: 11144704. 6: Delzell JE Jr, Lefevre ML. Urinary tract infections during pregnancy. Am Fam Physician. 2000 Feb 1;61(3):713-21. Review. Erratum in: Am Fam Physician 2000 Jun 15;61(12):3567. PubMed PMID: 10695584. 7: Ahuja GS, Thompson J. What role for antibiotics in otitis media and sinusitis? Postgrad Med. 1998 Sep;104(3):93-9, 103-4. Review. PubMed PMID: 9742906. 8: Dockrell DH, Poland GA. Hypercalcemia in a patient with hypoparathyroidism and Nocardia asteroides infection: a novel observation. Mayo Clin Proc. 1997 Aug;72(8):757-60. Review. PubMed PMID: 9276604. 9: Heifets LB. Antimycobacterial drugs. Semin Respir Infect. 1994 Jun;9(2):84-103. Review. Erratum in: Semin Respir Infect 1995 Jun;10(2):121. PubMed PMID: 7973175. 10: Giebink GS. Preventing otitis media. Ann Otol Rhinol Laryngol Suppl. 1994 May;163:20-3. Review. PubMed PMID: 8179264. 11: Wald ER. Antimicrobial therapy of pediatric patients with sinusitis. J Allergy Clin Immunol. 1992 Sep;90(3 Pt 2):469-73. Review. PubMed PMID: 1527339. 12: Kligman EW. Treatment of otitis media. Am Fam Physician. 1992 Jan;45(1):242-50. Review. PubMed PMID: 1728094. 13: Giebink GS, Canafax DM. Antimicrobial treatment of otitis media. Semin Respir Infect. 1991 Jun;6(2):85-93. Review. PubMed PMID: 1771307. 14: Grenier B. [Choice of antibiotic treatment in otitis media]. Rev Prat. 1990 Dec 1;40(28):2609-12. Review. French. PubMed PMID: 2281263. 15: Poland GA, Jorgensen CR, Sarosi GA. Nocardia asteroides pericarditis: report of a case and review of the literature. Mayo Clin Proc. 1990 Jun;65(6):819-24. Review. PubMed PMID: 2195244. 16: Lisby-Sutch SM, Nemec-Dwyer MA, Deeter RG, Gaur SM. Therapy of otitis media. Clin Pharm. 1990 Jan;9(1):15-34. Review. PubMed PMID: 2406100. 17: Smith GH. Oral cephalosporins in perspective. DICP. 1990 Jan;24(1):45-51. Review. PubMed PMID: 2405586. 18: Leonetti JP, Stankiewicz JA. Antimicrobial prophylaxis for recurrent otitis media. Otolaryngol Head Neck Surg. 1988 Jul;99(1):81-2. Review. PubMed PMID: 3140190. 19: Rodríguez RS, Sánchez-Sánchez C, de la Torre-González C. [Bacteriology and response to treatment with erythromycin-sulfisoxazole in children with acute otitis media]. Bol Med Hosp Infant Mex. 1987 Dec;44(12):728-34. Review. Spanish. PubMed PMID: 3322313. 20: Karp WB, Robertson AF. Vitamin E in neonatology. Adv Pediatr. 1986;33:127-47. Review. PubMed PMID: 3541528.

View History

Sapintoxin A

Sapintoxin A